Original Title: Coste-efectividad del cribado neonatal de la galactosemia clásica

Authors' objectives: To evaluate the cost-effectiveness of a newborn screening programme for classic galactosemia in Spain, comparing health results and costs of the screening with the clinical diagnosis.

Authors' results and conclusions: RESULTS: According to the results of this study, newborn screening for classic galactosemia is not cost-effective. For a lifetime horizon, the incremental costs per newborn are 6.49 €, and the incremental LYs per newborn are 0.000050135, giving an incremental cost effectiveness ratio of 129,464 €/LY. The sensitivity analysis shows the effect of the uncertainty on the results of the model. The sensitivity analysis estimated that the probability of a cost-effective classic galactosemia screening programme was inferior to 10% for a willingness to pay of 30,000 €/LY. CONCLUSIONS: The introduction of neonatal screening for classic galactosemia is not cost effective for a willingness to pay of 30,000 €/LY.

Authors' methods: We developed a cost-effectiveness model that compared two options: including classic galactosemia to the national screening programme and to not include this condition in the early detection programme and diagnose the condition by clinical diagnosis. The model takes into account the life expectancy of the newborns. The perspective of the analysis was that of the National Health Service and the Health Care System for the Autonomy and Care of Dependent Persons in Spain, expressing the costs in 2013 prices. We estimated the costs related to the screening programme including screening tests, confirmation tests, as well as treatment and follow up costs of those detected by the programme. Two alternative types of tests screening, MS/MS and fluorometric techniques. These costs were compared with those related to the clinical diagnosis of the condition. The differences in the costs were then compared with the difference on the effectiveness. Effectiveness was measured using Life Years gained (LY). Health outcomes and costs were discounted at a 3% rate. We undertook deterministic analyses and a probabilistic sensitivity analysis using Monte Carlo simulation.

Project Status: Completed

Year Published: 2013

URL for published report: https://sescs.es/coste-efectividad-del-cribado-neonatal-de-galactosemia-clasica/

English language abstract: An English language summary is available

Publication Type: Full HTA

Country: Spain

Organisation Name: Canary Health Service

Contact Address: Dirección del Servicio. Servicio Canario de la Salud, Camino Candelaria 44, 1ª planta, 38109 El Rosario, Santa Cruz de Tenerife

Contact Name: sescs@sescs.es

Contact Email: sescs@sescs.es